FDA 483 - Charles Parker, M.D. - January 18, 2019

An FDA inspection of Charles J. Parker, M.D., a clinical investigator in Salt Lake City, UT, revealed significant deviations from investigational plans. The firm failed to properly evaluate subjects against all screening criteria before administering investigational study drugs and did not adhere to protocol requirements for pre-drug administration exams. These findings indicate a lack of adherence to study protocols.